Cancers 2013, 5(4), 1456-1468; doi:10.3390/cancers5041456
Review

Bevacizumab for Glioblastoma—A Promising Drug or Not?

1 Department of Neurosurgery, Kyorin University Faculty of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo 181-8611, Japan 2 Department of Neuro-Oncology/Neurosurgery, International Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka-shi, Saitama-ken 350-1298, Japan
* Author to whom correspondence should be addressed.
Received: 11 October 2013; Accepted: 24 October 2013 / Published: 7 November 2013
(This article belongs to the Special Issue Glioblastoma)
PDF Full-text Download PDF Full-Text [343 KB, uploaded 7 November 2013 15:09 CET]
Abstract: Two double blind, placebo-controlled, and randomized phase III studies were conducted, and the results including OS’s were reported at the ASCO Meeting in June 2013, which was the beginning of confusion surrounding this topic. This is a review article not only summarizing the previous evidence, but also looking beyond.
Keywords: bevacizumab; glioblastoma; chemotherapy

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Nagane, M.; Nishikawa, R. Bevacizumab for Glioblastoma—A Promising Drug or Not? Cancers 2013, 5, 1456-1468.

AMA Style

Nagane M, Nishikawa R. Bevacizumab for Glioblastoma—A Promising Drug or Not? Cancers. 2013; 5(4):1456-1468.

Chicago/Turabian Style

Nagane, Motoo; Nishikawa, Ryo. 2013. "Bevacizumab for Glioblastoma—A Promising Drug or Not?" Cancers 5, no. 4: 1456-1468.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert